Vernalis and Biogen Idec drop Phase II Parkinson's hope, vipadenant
This article was originally published in Scrip
Executive Summary
Vernalis and its partner Biogen Idec have decided to discontinue the development of Phase II Parkinson's drug vipadenant, citing "preclinical toxicology studies". The companies plan to continue to work together with an "alternative" adenosine A